1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD.SW
Gilead Sciences, Inc.CH flagSwiss Exchange
110.83
USD
-3.95
- -
137.59BMarket Cap
Gilead Sciences, Inc.
GILD.SW
(Swiss Exchange)

Recent

price

110.83

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
19.64
21.74
21.74
21.73
23.06
23.67
23.92
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.1
4.96
3.66
4.54
0.38
6.84
7.41
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
6.5
9.06
7.23
5.95
8.26
7.6
8.23
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.74
2.87
2.96
3.05
3.14
3.22
3.24
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
11.44
13
12.5
13.06
9.22
11.04
11.37
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-18.31
-16.5
-12.75
-9.63
-7.23
-2.15
-1.02
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1,257
1,256
1,255
1,248
1,247
1,244
1,243
Basic Weighted Avg Shares
7,949
8,385
9,702
11,202
24,890
32,639
30,390
26,107
22,127
22,449
24,689
27,305
27,281
27,116
28,754
29,442
29,734
Sales/Revenue/Turnover
49.84
45.2
41.33
40.39
61.33
68
58.02
54.1
42.02
41.6
40.21
39.76
40.23
32.59
36.85
39.74
40.02
Operating Margin (%)
265
302
278
345
1,050
1,098
1,158
1,286
1,429
1,404
1,480
2,050
2,103
2,693
2,767
2,760
2,753
Depreciation Expense
2,901
2,804
2,592
3,075
12,101
18,108
13,501
4,628
5,455
5,386
123
6,225
4,592
5,665
480
8,510
9,216
Net Income, GAAP
26.16
23.61
28.74
27.35
18.83
16.4
21.11
65.67
29.99
- -
94.67
25.09
21.47
18.18
30.58
13.13
14.08
Effective Tax Rate (%)
36.5
33.43
26.72
27.45
48.62
55.48
44.43
17.73
24.65
23.99
0.5
22.8
16.83
20.89
1.67
28.9
30.99
Profit Margin (%)
3,243
11,404
1,918
590
11,953
14,872
10,370
20,188
25,231
20,537
4,599
3,162
3,205
4,805
7,169
6,529
9,166
Working Capital
2,839
7,606
7,055
3,939
11,921
21,073
26,346
30,795
24,574
22,094
28,645
25,179
22,957
23,189
24,896
22,129
20,861
LT Debt
6,122
6,867
9,544
11,745
15,819
19,113
19,363
20,501
21,534
22,650
18,221
21,064
21,209
22,749
19,246
22,618
23,431
Total Equity
33.67
24.36
17.96
18.43
53.74
54.43
32.6
9.75
12.67
- -
1.1
16.76
18.29
15.25
15.52
21.77
23.25
Return on Invested Capital (%)
72.04
41.2
26.44
26.22
64.57
56.48
33.35
10.24
12.52
- -
0.47
15.76
12.76
15.81
2.92
24.51
27.99
Return on Capital (%)
182.43
189.3
94.53
62.66
128.45
117.83
74.68
24.9
28.68
28.04
0.73
40.54
28.69
35.41
3.45
67.46
73.54
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2,806
2,807
1,313
LT Borrowings
22,135
22,129
20,861
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,242
1,241
1,242
Market Capitalization
- -
- -
136,618

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
17,874
18,342
18,641
Cash, Cash Equivalents & STI
7,349
9,613
7,643
Accounts Receivable, Net
5,095
4,913
4,741
Inventories
1,785
1,774
1,914
Total Current Liabilities
12,297
11,813
9,475
Payables & Accruals
5,739
5,144
4,763
ST Debt
2,806
2,807
1,313
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.35%
5.13%
17.52%
Free Cash Flow
-4.97%
6.3%
-8.24%
Net Income, GAAP
636.72%
1,307.9%
1,672.92%
Sales/Revenue/Turnover
-0.64%
3.67%
2.39%
Total Cash Common Dividend
8.17%
3.03%
2.17%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6,686
6,953
7,545
7,569
28,754
2025
6,667
7,081
7,769
7,924
29,442
2026
6,960
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-3.34
1.29
1
1.43
0.38
2025
1.06
1.57
2.46
1.76
6.84
2026
1.63
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.79
0.78
0.79
0.78
3.14
2025
0.81
0.8
0.81
0.8
3.22
2026
0.84
- -
- -
- -
- -
Similar Companies
Ambrx Biopharma Inc. (AMAM)
SAB Biotherapeutics, Inc. (SABSW)
Lipella Pharmaceuticals Inc. (LIPO)
NightHawk Biosciences, Inc. (NHWK)
Arcutis Biotherapeutics, Inc. (ARQT)
Green Cross Holdings Corporation (005257.KS)
Business
Gilead Sciences, Inc. (Nasdaq: GILD) is a biopharmaceutical company focused on researching, developing and commercializing innovative therapeutics for life-threatening diseases in virology, oncology and inflammation. The company offers a broad portfolio of products including antiviral treatments for HIV/AIDS such as Biktarvy, Descovy, Truvada (as pre-exposure prophylaxis or PrEP), Genvoya and Trospium; therapies for viral hepatitis such as Veklury (remdesivir) for COVID-19, Vemlidy and Viread; oncology offerings like Yescarta and Tecartus (CAR T-cell therapies), Trodelvy (for breast cancer) and Zepzelca; and Livdelzi (seladelpar) for primary biliary cholangitis; as well as investigational candidates across small molecules, biologics and antibody-drug conjugates. Gilead Sciences operates in more than 35 countries worldwide, with manufacturing and research facilities in the United States (including California, Connecticut and Washington), Canada and the Asia-Pacific region (Australia, China, Japan and Korea). Founded in 1987 and headquartered in Foster City, California, the company employs over 17,000 people and maintains a robust pipeline of more than 55 clinical programs. Recent developments include the March 2024 acquisition of CymaBay Therapeutics for $4.3 billion, adding seladelpar (branded Livdelzi) following FDA accelerated approval in August 2024; a January 2025 strategic partnership with LEO Pharma acquiring preclinical oral STAT6 inhibitors and targeted protein degraders for inflammatory diseases, with Gilead securing exclusive global rights to oral programs for up to $1.7 billion; collaborations with Terray Therapeutics and Tubulis on small-molecule and antibody-drug conjugate therapies; a $32 billion U.S. expansion announced in 2025 featuring a new Pharmaceutical Development and Manufacturing Technical Development Center in Foster City, three new facilities and upgrades to enhance AI-driven drug discovery, biologics capacity and localized manufacturing while creating 800 domestic jobs by 2028; and the opening of its first international research lab in Oxford, England, in 2024.